阿尔茨海默病（AD）临床治疗效果不佳。p38MAPK参与 AD 发病机制，针对 MAPK 的研究尝试探究其对记忆等的影响。相关 MAPK 抑制剂临床试验有积极成果，但存在问题。本文聚焦 MAPK 干预疗法治疗 AD 的临床研究，值得关注。 阿尔茨海默病现状 阿尔茨海默病（AD ...

Enrollment and initial dosing of PAS-004 at 30 milligrams has begun in three patients with MAPK pathway-driven advanced solid ...

水稻粒型和叶角是决定产量的关键农艺性状，但其调控机制尚不明晰。研究人员开展了 OsBSKs（BRASSINOSTEROID - SIGNALING KINASES）和 OsMAPKs（MITOGEN ACTIVATED PROTEIN KINASE）调控水稻粒型和叶角的研究，发现了其关键作用及调控机制，为水稻增产研究提供重要依据。 粒型和 ...

A study conducted at the State University of Campinas (UNICAMP) in Brazil investigated the process of muscle pain ...

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Shares of Pasithea Therapeutics Corp. (KTTA) soared as high as about 150% on Tuesday morning before paring back some of the ...

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...